Medical treatment of prolactinomas.

Abstract

Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 40% of all pituitary adenomas. The most important clinical problems associated with prolactinomas are hypogonadism, infertility and hyposexuality. In patients with macroprolactinomas, mass effects, including visual field defects, headaches and neurological disturbances, can also occur. The objectives of therapy are normalization of prolactin levels, to restore eugonadism, and reduction of tumor mass, both of which can be achieved in the majority of patients by treatment with dopamine agonists. Given their association with minimal morbidity, these drugs currently represent the mainstay of treatment for prolactinomas. Novel data indicate that these agents can be successfully withdrawn in a subset of patients after normalization of prolactin levels and tumor disappearance, which suggests the possibility that medical therapy may not be required throughout life. Nevertheless, multimodal therapy that involves surgery, radiotherapy or both may be necessary in some cases, such as patients who are resistant to the effects of dopamine agonists or for those with atypical prolactinomas. This Review reports on efficacy and safety of pharmacotherapy in patients with prolactinomas.

• Authors: Annamaria Colao, Silvia Savastano
• Journal: Nature reviews. Endocrinology (Nat Rev Endocrinol) Vol. 7 Issue 5 Pg. 267-78 (May 2011) ISSN: 1759-5037 [Electronic] England
• PMID: 21423245 (Publication Type: Journal Article, Review)

Chemical References

• Dopamine Agonists
• Prolactin

Topics

• Dopamine Agonists (therapeutic use)
• Humans
• Hypogonadism (drug therapy, physiopathology, radiotherapy, surgery)
• Prolactin (metabolism)
• Prolactinoma (drug therapy, physiopathology, radiotherapy, surgery)